Results 161 to 170 of about 27,407 (265)

Meta-analyses overgeneralize SGLT2 inhibitor effectiveness in population with low albuminuria, no diabetes, no heart failure and no atherovascular heart disease. [PDF]

Nephrol Dial Transplant
Murea M, Basile C, Piccoli GB.
europepmc   +1 more source

Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2,
Jelle M. Beernink, Gozewijn D. Laverman, Hiddo J. L. Heerspink   +2 more
wiley   +1 more source

Diabetic Ketoacidosis Associated With Painless Thyroiditis in a Patient Treated With an SGLT2 Inhibitor. [PDF]

Case Rep Endocrinol
Aotani R, Ohkuma T, Oshiro A, Okamura K, Ago T.   +4 more
europepmc   +1 more source

α‐Hydroxybutyrate Association With Incident Type 2 Diabetes Over 10 Years Across Different Glycemic States

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To investigate the association between baseline plasma α‐hydroxybutyrate (α‐HB), an organic acid derived from aminoacid catabolism and glutathione anabolism, and the 10‐year incidence of Type 2 diabetes (T2DM). Materials and Methods This prospective study analysed 1349 participants from the Swedish PAROKRANK study.
Elena Fortin, Anna Norhammar, David Stadler, Peter L. Herzog, Giulia Ferrannini, Ele Ferrannini   +5 more
wiley   +1 more source

Efficacy and safety of SGLT2 inhibitor on insulin resistance and hyperglycemia in Werner syndrome-A case report. [PDF]

J Diabetes Investig
Yagi T, Aotani D, Hasegawa C, Shimizu Y, Koyama H, Maezawa Y, Yokote K, Tanaka T.   +7 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE‐RWD)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Although finerenone has shown efficacy in randomized trials, evidence from routine clinical practice remains limited. We aimed to assess the real‐world effectiveness and safety of finerenone in people with type 2 diabetes (PWT2D) and chronic kidney disease (CKD), with a particular focus on residual cardiorenal risk as reflected by changes ...
Oscar Moreno‐Pérez, Antonio Tejera‐Muñoz, Patricia Tomás‐Gómez, Federico Vázquez‐San Miguel, Virginia Soria‐Utrilla, Ada María Roldán‐Sánchez, Maya Sánchez‐Baya, Jersy Cárdenas‐Salas, Blanca Timón‐Vázquez, Juan J. Gorgojo‐Martínez, Ines Modrego‐Pardo, Irea Fernández‐Xove, Jose Carlos Fernández‐García, Rebeca Reyes‐García   +13 more
wiley   +1 more source

Disentangling Uric Acid and Renal Pathways in SGLT2 Inhibitor Effects After Acute Myocardial Infarction: A Retrospective Mediation Analysis. [PDF]

Biomedicines
Suciu IM, Muntean C, Gaiță L, Mateoc-Sîrb T, Vlad DC, Timar B, Gaiță D.   +6 more
europepmc   +1 more source

Sodium Butyrate Attenuates Renal Fibrosis by Regulating Glycolysis and Histone H4K12 Lactylation in Diabetic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background The role of histone lactylation in diabetes associated renal fibrosis remains poorly defined. In this study, we investigated the contribution of histone H4 lysine 12 lactylation (H4K12la) to abnormal glycolysis and renal fibrogenesis in diabetic kidney disease (DKD) and evaluated sodium butyrate (NaB) as a potential therapeutic ...
Ping He, Mingxiu Wang, Hang Mei, Yue Liu, Min Wang, He Sun, Yali Peng, Xuan Ban, Yue Wang, Xiaofang Tang, Qiuling Fan   +10 more
wiley   +1 more source

sncRNA levels predict SNORD105B is a novel biomarker of chronic kidney disease risk and SGLT2 inhibitor response in type 2 diabetes. [PDF]

Mol Ther Nucleic Acids
de Klerk JA, Slieker RC, Beulens JWJ, Peerlings JHD, Mei H, Elders PJM, van Zonneveld AJ, van Raalte DH, Bijkerk R, 't Hart LM.   +9 more
europepmc   +1 more source

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain, Pierre Bel Lassen, Christine Bellanné‐Chantelot, Marie Christine Vantyghem, Hippolyte Dupuis, Tiphaine Vidal‐Trecan, Nicolas Chevalier, Danièle Dubois‐Laforgue, Sophie Lamothe, Camille Vatier, Orianne Villard, René Valéro, Claire Briet, Corinne Vigouroux, Cécile Ciangura, Chloé Amouyal   +15 more
wiley   +1 more source